CN1148192C - 细胞保护剂氨磷汀制剂及其制备方法 - Google Patents
细胞保护剂氨磷汀制剂及其制备方法 Download PDFInfo
- Publication number
- CN1148192C CN1148192C CNB001190385A CN00119038A CN1148192C CN 1148192 C CN1148192 C CN 1148192C CN B001190385 A CNB001190385 A CN B001190385A CN 00119038 A CN00119038 A CN 00119038A CN 1148192 C CN1148192 C CN 1148192C
- Authority
- CN
- China
- Prior art keywords
- amifostine
- preparation
- ethyol
- present
- freezing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 229960001097 amifostine Drugs 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title abstract description 7
- 238000007710 freezing Methods 0.000 claims abstract description 8
- 230000008014 freezing Effects 0.000 claims abstract description 8
- 238000010979 pH adjustment Methods 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- 229940098617 ethyol Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- 230000001120 cytoprotective effect Effects 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 239000000843 powder Substances 0.000 abstract description 17
- 238000002347 injection Methods 0.000 abstract description 7
- 239000007924 injection Substances 0.000 abstract description 7
- 238000004108 freeze drying Methods 0.000 abstract description 4
- 239000007787 solid Substances 0.000 abstract description 4
- 239000003223 protective agent Substances 0.000 abstract description 2
- 239000013078 crystal Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 7
- 238000009527 percussion Methods 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 4
- 229960004821 amikacin Drugs 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000003924 normoblast Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
- 229930195573 Amycin Natural products 0.000 description 1
- ASSMDJONQXBMSW-IDWMTUBTSA-N N(=[N+]=[N-])[C@H]1[C@H](C(O[C@@H]1CO)CC=1C(NC(NC1)=O)=O)O Chemical compound N(=[N+]=[N-])[C@H]1[C@H](C(O[C@@H]1CO)CC=1C(NC(NC1)=O)=O)O ASSMDJONQXBMSW-IDWMTUBTSA-N 0.000 description 1
- XDVMCVGTDUKDHL-UHFFFAOYSA-N [amino(2-azaniumylethylsulfanyl)methylidene]azanium;dibromide Chemical compound Br.Br.NCCSC(N)=N XDVMCVGTDUKDHL-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000678 band cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000001501 megacaryocyte Anatomy 0.000 description 1
- 210000001237 metamyelocyte Anatomy 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 210000003950 neutrophilic myelocyte Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000468 rubriblast Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了稳定性改进的细胞保护剂氨磷汀粉针剂及其制备方法，本方法无需冻干，在无菌条件下通过调节pH，冷冻，得到晶型大小合适的单一成份的固体，过筛后可直接分装成粉针剂，其稳定性优于目前国外上市产品。
Description
技术领域
本发明涉及稳定性改进的氨磷汀(即硫代磷酸二氢S-2(3-氨丙氨基)乙酯、amifostine)无菌粉针剂及其制备方法。
背景技术
氨磷汀为一种广谱细胞保护剂。以前作为军用抗辐射剂，现用作放射治疗和化学治疗的保护药。在减少抗癌药物如环磷酰胺、氯氨铂、阿霉素和抗HIV药物如3-叠氮基-3-脱氧胸苷的副作用方面疗效显著，并且不影响抗癌药或抗HIV药物的疗效。目前市售氨磷汀产品由美国生命科学有限公司独家生产，商品名为ETHYOL。该产品只有冻干粉针剂，但通过低压冻干法生产的这种非晶形式是热不稳定的。这种冻干的制剂必须保持在约-20℃的温度下和在约-70℃至-20℃的温度下运输，才可避免该配制的产品降解，这不但不方便，而且需要特殊的包装和大量的运费。美国生命科学有限公司认为：“氨磷汀非冻干型粉针剂‘干装’或‘粉装’方法，在包装散装的固体氨磷汀时涉及大量的实际问题。这类问题包括：粉末的人工操作法中的困难，需要将粉末磨至可接受的颗粒尺寸和流动性，保持无粉尘、无菌条件中的困难，和将精确剂量的固体氨磷汀装入每个小瓶中的困难。”(参见CN93117436.8)
发明内容
本发明的目的在于提供一种稳定的非冻干型的氨磷汀无菌粉针剂，该粉针由长度大小适中的氨磷汀结晶组成。本发明的目的还在于提供一种制备稳定的非冻干型氨磷汀无菌粉针剂的工业化方法，所得结晶长度大小适中，无需磨即具有良好流动性，可精确装瓶。
本发明的技术方案是：一种氨磷汀粉针剂，其特征在于由氨磷汀单一成分的结晶组成。所述的氨磷汀粉针剂，其特征在于氨磷汀的结晶中含三分子的结晶水，结晶颗粒长度为300～700μm。本发明的还提供一种氨磷汀粉针剂的制备方法，其特征在于将氨磷汀原料药溶于注射用水中，用碱液调pH至6.6～7.4后，加入乙醇，冷冻，析出结晶。所述氨磷汀粉针剂的制备方法，用碱液调节pH至6.8～7.2较好，用碱液调节pH至7.0～7.2亦好，加入乙醇，冷冻析出结晶，所用碱液可以是氢氧化钠、氢氧化钾、碳酸氢钠、碳酸钠溶液或氨液，析出颗粒长度为300～700μm的氨磷汀结晶。
所述氨磷汀粉针剂的制备方法，其特征在于，结晶时温度可以是-16～-23℃。
氨磷汀是以无水物计算的。在化疗、放疗药物使用前半小时内静脉注射，按体表面积计算，化疗时每平方米800mg，放疗时每平方米200mg，具体病例应遵医嘱。
本发明的有益效果在于产品的稳定性增加，无需冷藏，可于室温下保存二年。将本发明产品(下称南京振中氨磷汀非冻干粉针剂)与常规冻干剂及美国氨磷汀专利处方制品进行稳定性比较实验，表明本发明产品的稳定性优于这两种产品。参见表1。
表1 常规冻干剂、美国专利冻干处方与南京振中非冻干粉针剂的
稳定性比较
注：所采用的条件(40℃、RH75％、90天)是美国FDA规定的加速试验方法，在此种条件下如果药物能耐受不变质，预测药物在室温条件下可贮存二年。含量测定采用经典的碘量法。
将本发明产品与国内外注射用氨磷汀进行药效比较，证明本产品总体疗效略优于目前国外产品。见表2。
表2 国内外注射用氨磷汀药效比较表
| 项目分类 | Z200+CY | Z100+CY | Z50+CY | E200+CY | CY | 对照 |
| 原始红细胞早幼红细胞中幼红细胞晚幼红细胞 | 00.25±0.282.05±0.61**8.45 ±2.73** | 01.15±0.783.67±1.41**6.80±3.93* | 00.48±0.391.92±1.61*4.56±3.20 | 001.25±0.84*2.57±3.45* | 000.20±0.201.73±0.38 | 02.00±1.896.05±2.66**12.60±4.90** |
| 原始粒细胞早幼粒细胞中性中幼粒细胞中性晚幼粒细胞中性杆状核细胞中性分叶核细胞 | 0.75±0.903.55±3.1719.45±7.14**32.45±6.01**28.50±10.691.90±1.67 | 3.40±2.002.67±2.6622.53±6.90**30.13±3.71*24.93±1.941.67±1.23 | 3.68±2.172.56±1.4225.04±3.24**37.12±3.31**17.04±4.840.80±0.25 | 7.40±5.336.00±4.4126.40±9.70**35.33±5.70**14.80±10.880.65±0.53 | 10.53±7.245.80±2.1148.80 ±7.6416.20±11.477.47±4.210.47±0.59 | 0.40±0.490.85±0.7524.45±4.03**18.40±5.8013.95±7.281.10±0.77 |
| 成熟淋巴细胞 | 2.55±1.37 | 2.60±1.91 | 6.80±4.02 | 4.90±2.97 | 7.80±4.44 | 17.60±6.69 |
| 巨核细胞 | 9.25±1.85 | 10.67±7.43 | 8.20±5.19 | 14.00±9.94 | 12.33±7.41 | 23.00±13.35 |
注：(1)Z为注射用氨磷汀，CY为化疗药环磷酰胺，E为国外注射用氨磷汀；与CY组比较*P＜0.05 **P＜0.01；
(2)Z200+CY组表示使用南京振中氨磷汀产品200mg/kg效果；
(3)Z100+CY组表示使用南京振中氨磷汀产品100mg/kg效果；
(4)Z50+CY组表示使用南京振中氨磷汀产品50mg/kg效果；
(5)E200+CY组表示使用国外氨磷汀产品200mg/kg效果；
(6)CY组表示不使用氨磷汀效果；
(7)对照组表示正常值。
本发明的氨磷汀粉针剂制备方法中不加赋形剂，不经过冷冻干燥而采用真空干燥，避免了冻干粉针剂因反复冻溶(即反复降温升温)过程可能导致的制剂不稳定。制备过程中通过调pH获得大小合适的结晶，氨磷汀结晶的颗粒长度为300～700μm，这种大小的结晶可过30目筛直接装瓶。从而克服了“粉末人工操作中的困难”，无需“将粉末磨至可接受的颗粒尺寸和流动性”，克服了“保持无粉尘无菌条件中的困难和将精确剂量的固体装入每个小瓶中的困难”。
具体实施方式
实施例1：按文献方法制备氨磷汀原料，参见童增寿等药学学报1981，16(4)，302。在无菌条件下(通过国家GMP论证的车间)，室温18～22℃时，将50克氨磷汀原料药搅拌溶解在250毫升水中，滴加碳酸氢钠饱和溶液数滴，溶解完全，测溶液pH值在7.0～7.2，缓慢加入乙醇125毫升，放入冰柜中6～8小时，使其析出白色结晶性粉末，结晶颗粒长度为300～700μm，抽滤后，减压真空干燥，测水份后，过30目筛，分装于小瓶中。
实施例2：在无菌条件下(通过国家GMP论证的车间)，室温(同上)，取100克氨磷汀原料药，溶解于500毫升水中，滴加碳酸氢钠饱和溶液数滴，调溶液pH值在6.8～7.0，加无水乙醇250毫升，析晶(同上)，结晶颗粒长度为300～700μm，抽滤后，置五氧化二磷真空干燥器中干燥，测水份后，过30目筛，分装于小瓶。
Claims (6)
1.一种细胞保护剂氨磷汀粉针剂的制备方法，其特征在于将氨磷汀原料药溶于注射用水中，用碱液调pH至6.6～7.4后，加入乙醇，冷冻结晶。
2.根据权利要求1所述氨磷汀粉针剂的制备方法，其特征在于将氨磷汀原料药溶于注射用水中，用碱液调pH至6.8～7.2后，加入乙醇，冷冻，结晶。
3.根据权利要求2所述氨磷汀粉针剂的制备方法，其特征在于将氨磷汀原料药溶于注射用水中，用碱液调pH至7.0～7.2后，加入乙醇，冷冻，结晶。
4.根据权利要求2所述氨磷汀粉针剂的制备方法，其特征在于所用碱液是氢氧化钠、氢氧化钾、碳酸氢钠、碳酸钠溶液或氨液。
5.根据权利要求2所述氨磷汀粉针剂的制备方法，其特征在于冷冻结晶时温度是-16～-23℃。
6.根据权利要求2所述氨磷汀粉针剂的制备方法，其特征在于冷冻结晶的时间为6-8小时。
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001190385A CN1148192C (zh) | 2000-10-19 | 2000-10-19 | 细胞保护剂氨磷汀制剂及其制备方法 |
| AU2001248229A AU2001248229A1 (en) | 2000-10-19 | 2001-02-28 | Amifostine powder injection and its method of process |
| PCT/CN2001/000310 WO2002032401A1 (en) | 2000-10-19 | 2001-02-28 | Amifostine powder injection and its method of process |
| RU2003114443/15A RU2264808C2 (ru) | 2000-10-19 | 2001-02-28 | Амифостин в виде порошка для инъекций и способ его получения |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001190385A CN1148192C (zh) | 2000-10-19 | 2000-10-19 | 细胞保护剂氨磷汀制剂及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1291475A CN1291475A (zh) | 2001-04-18 |
| CN1148192C true CN1148192C (zh) | 2004-05-05 |
Family
ID=4587433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001190385A Expired - Lifetime CN1148192C (zh) | 2000-10-19 | 2000-10-19 | 细胞保护剂氨磷汀制剂及其制备方法 |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN1148192C (zh) |
| AU (1) | AU2001248229A1 (zh) |
| RU (1) | RU2264808C2 (zh) |
| WO (1) | WO2002032401A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007096901A1 (en) * | 2006-02-24 | 2007-08-30 | Natco Pharma Limited | Novel dihydrate form of amifostine and process for its preparation |
| CN101347412B (zh) * | 2008-09-02 | 2011-07-27 | 大连美罗药业股份有限公司 | 三水合氨磷汀结晶冻干制剂及其制备方法 |
| CN102286019B (zh) * | 2011-07-11 | 2014-02-05 | 大连美罗大药厂 | 二水合3-氨基丙基胺乙基硫代磷酸的制备方法 |
| CN109694386B (zh) * | 2019-01-23 | 2021-03-23 | 美罗药业股份有限公司 | 氨磷汀三水合物的制备方法 |
| CN115902061B (zh) * | 2022-11-19 | 2025-02-07 | 四川汇宇制药股份有限公司 | 气相色谱法测定氨磷汀中残留溶剂的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5167947A (en) * | 1989-10-26 | 1992-12-01 | Southwest Research Institute | Enhancement of absorption of radioprotective drugs |
| SG47101A1 (en) * | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
-
2000
- 2000-10-19 CN CNB001190385A patent/CN1148192C/zh not_active Expired - Lifetime
-
2001
- 2001-02-28 WO PCT/CN2001/000310 patent/WO2002032401A1/zh not_active Ceased
- 2001-02-28 RU RU2003114443/15A patent/RU2264808C2/ru active
- 2001-02-28 AU AU2001248229A patent/AU2001248229A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002032401A1 (en) | 2002-04-25 |
| RU2264808C2 (ru) | 2005-11-27 |
| AU2001248229A1 (en) | 2002-04-29 |
| CN1291475A (zh) | 2001-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210023011A1 (en) | Method and system for producing high purity vancomycin hydrochloride | |
| CN1148192C (zh) | 细胞保护剂氨磷汀制剂及其制备方法 | |
| CA2955256C (en) | High purity oritavancin and method of producing same | |
| US10617649B2 (en) | Preparation method of azacitidine for injection | |
| AU2008245821B2 (en) | Stabilization of liquid solutions of recombinant protein for frozen storage | |
| CN102247319B (zh) | 一种含有胸腺法新的药用组合物及其制备方法 | |
| CN101756897B (zh) | 一种盐酸克林霉素注射剂及其制备方法 | |
| EP1146863B1 (de) | Lyophilisate mit verbesserter rekonstituierbarkeit | |
| AU690143B2 (en) | Stable lyophilized thiotepa composition | |
| SA97180719B1 (ar) | تركيبات صيدلية للتجفيف بالتجميد | |
| CN101297809A (zh) | 头孢哌酮钠与舒巴坦钠混粉的制备方法 | |
| CN102579372B (zh) | 一种盐酸吉西他滨冻干组合物及其制备方法 | |
| CN101152152A (zh) | 注射用替加环素组合物及其制备方法 | |
| EP3068370A2 (en) | Stable pharmaceutical compositions | |
| CN102949356B (zh) | 一种含有胸腺法新的冻干制剂 | |
| CN102757471A (zh) | 一种新活性三磷酸胞苷二钠化合物及其药物组合物 | |
| US5169834A (en) | Compositions and method for reducing vial breakage during lyophilization | |
| CN113797171A (zh) | 聚乙二醇化重组人粒细胞集落刺激因子冻干制剂 | |
| CN100409848C (zh) | 一种稳定的氢溴酸高乌甲素冻干粉针剂及其制备方法 | |
| AU2020480182B2 (en) | Fosphenytoin sodium solid composition, lyophilization method, and use of fosphenytoin sodium solid composition | |
| CN101347613B (zh) | 几乎不含亚基的糖蛋白的组合物及其制备方法 | |
| CN1397280A (zh) | 注射羟基喜树碱冻干粉针剂及制备方法 | |
| CN102309747B (zh) | 高纯度绝经期促性腺素冻干针剂 | |
| CN1424051A (zh) | 一种注射用蝎毒冻干粉针剂 | |
| CN104083388A (zh) | 复方甘草酸铵的特种超细粉体冻干制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: NANJING KANGHAI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NANJING ZHENZHONG BIOLOGICAL ENGINEERING CO., LTD. Effective date: 20040702 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20040702 Address after: 210061 Nanjing hi tech Industrial Development Zone, Jiangsu Patentee after: Kanghai Pharmaceutical Co.,Ltd. Nanjing Address before: 210061 hi tech Industrial Development Zone, Jiangsu, Nanjing Patentee before: Nanjing Zhenzhong Bioengineering Co.,Ltd. |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Nanjing Cike Pharmaceutical Co.,Ltd. Assignor: Kanghai Pharmaceutical Co.,Ltd. Nanjing Contract fulfillment period: 2008.7.30 to 2013.7.29 Contract record no.: 2008320000282 Denomination of invention: Cell-protecting amifostine and its preparing process Granted publication date: 20040505 License type: Exclusive license Record date: 20080923 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENCE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.7.30 TO 2013.7.29 Name of requester: NANJING SIKE PHARMACEUTICAL CO., LTD. Effective date: 20080923 |
|
| ASS | Succession or assignment of patent right |
Owner name: NANJING SIKE PHARMA CO., LTD. Free format text: FORMER OWNER: NANJING KANGHAI PHARMACEUTICAL CO., LTD. Effective date: 20101213 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C56 | Change in the name or address of the patentee |
Owner name: NANJING LVYE SIKE PHARMA CO., LTD. Free format text: FORMER NAME: NANJING SIKE PHARMA CO., LTD. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210061 HIGH-TECH INDUSTRIAL DEVELOPMENT ZONE, NANJING CITY, JIANGSU PROVINCE TO: 210061 NEW + HIGH TECHNOLOGY INDUSTRY DEVELOPMENT ZONE, NANJING CITY, JIANGSU PROVINCE |
|
| CP03 | Change of name, title or address |
Address after: High road 210061 Jiangsu city of Nanjing province high tech Industrial Development Zone No. 28 Patentee after: NANJING LVYE PHARMACEUTICAL CO.,LTD. Address before: 210061 hi tech Industrial Development Zone, Jiangsu, Nanjing Patentee before: Nanjing Cike Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20101213 Address after: 210061 hi tech Industrial Development Zone, Jiangsu, Nanjing Patentee after: Nanjing Cike Pharmaceutical Co.,Ltd. Address before: 210061 Nanjing hi tech Industrial Development Zone, Jiangsu Patentee before: Kanghai Pharmaceutical Co.,Ltd. Nanjing |
|
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: High road 210061 Jiangsu city of Nanjing province high tech Industrial Development Zone No. 28 Patentee after: NANJING LUYE PHARMACEUTICAL Co.,Ltd. Address before: High road 210061 Jiangsu city of Nanjing province high tech Industrial Development Zone No. 28 Patentee before: NANJING LVYE PHARMACEUTICAL CO.,LTD. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20040505 |
|
| CX01 | Expiry of patent term |